Pulmonary Arterial Hypertension Market Expands as Advanced Therapies and Drug Approvals Drive Global Growth | Top Companies are Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company

The global pulmonary arterial hypertension market size reached US$ 8.04 Billion in 2024 from US$ 7.59 Billion in 2023 and is expected to reach US$ 14.11 Billion by 2033, growing at a CAGR of 6.5% during the forecast period 2025-2033.

Pulmonary Arterial Hypertension (PAH) is a progressive disorder characterized by high blood pressure in the arteries of the lungs, leading to heart strain and potential failure. It is associated with genetic mutations, autoimmune diseases, and congenital heart conditions. Symptoms include shortness of breath, chest pain, and fatigue. The PAH market is expanding due to the need for targeted therapies and advanced diagnostics. Innovations in drug formulations and clinical trials are shaping future treatment landscapes.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Pulmonary Arterial Hypertension Market Landscape:- https://datamintelligence.com/download-sample/pulmonary-arterial-hypertension-market?Ranjith

☛ Pulmonary Arterial Hypertension Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In September 2025, United Therapeutics Corporation announced positive Phase 3 results for Tyvaso DPI® (treprostinil inhalation powder) showing significant improvement in exercise capacity and pulmonary vascular resistance in PAH patients. The company is now seeking FDA approval for expanded indications.

✅ In August 2025, Johnson & Johnson (Janssen Pharmaceuticals) initiated a Phase 2 trial evaluating its oral prostacyclin receptor agonist for patients with WHO Group 1 PAH. The compound aims to improve endothelial function and delay disease progression.

✅ In July 2025, Gilead Sciences launched its digital health monitoring platform for patients receiving Letairis® (ambrisentan), integrating wearable-based cardiopulmonary analytics to support real-time therapy optimization.

✅ In May 2025, Merck & Co., Inc. announced the expansion of its cardiopulmonary R&D division in Boston, focusing on novel endothelin receptor antagonists (ERAs) and combination therapy trials for resistant PAH cases.

Japan: Recent Industry Developments

✅ In September 2025, Nippon Shinyaku Co., Ltd. launched a new oral selexipag formulation with enhanced bioavailability for the treatment of PAH, developed in collaboration with Actelion Pharmaceuticals (J&J).

✅ In August 2025, Ono Pharmaceutical Co., Ltd. partnered with Kyoto University Hospital to advance gene therapy research targeting BMPR2 mutations-a key genetic cause of heritable pulmonary arterial hypertension.

✅ In July 2025, Toray Industries, Inc. introduced a biodegradable nanoparticle drug delivery system designed to improve pulmonary absorption and reduce systemic side effects of PAH medications.

✅ In June 2025, Shionogi & Co., Ltd. began preclinical trials of a dual-pathway modulator that targets both nitric oxide and prostacyclin signaling to achieve enhanced pulmonary vasodilation.

☛ Pulmonary Arterial Hypertension Market Competitive Landscape:

Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc, GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG, Pfizer Inc, United Therapeutics Corporation.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/pulmonary-arterial-hypertension-market?Ranjith

☛ Segments Covered in the Pulmonary Arterial Hypertension Market:

By Drug Class: Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5 (PDE-5), Endothelin Receptor Antagonists (ERA), and Others

By Route of Administration: Inhalation, Injectable and Oral Administration

By Distribution channel: Hospital Pharmacy, Pharmacy stores, and Others

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Pulmonary Arterial Hypertension Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=pulmonary-arterial-hypertension-market?Ranjith

☛ Regional Analysis for Pulmonary Arterial Hypertension Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.